Oncoc4 Inc.

Oncoc4 Inc. focuses on clinical research in metastatic non-small cell lung cancer, with attention to disease progression after prior PD-1 and PD-L1 immunotherapy exposure.

• Metastatic non-small cell lung cancer
• Post-immunotherapy disease progression
• Advanced lung cancer treatment

The sponsor’s research activity is centered on treatment options for patients with advanced lung cancer in the setting of resistance or progression after checkpoint inhibitor therapy.